Spectrum Success Stories

TEAR DUCT STIMULATOR FOR DRY EYE (TrueTear)
Spectrum-Biodesign pilot grant in 2012.
$24M VC financing for start-up.
Allergan buys for $125M in 2015.
FDA approval in 2016.

CLINICAL RESEARCH CONSENT VIDEOS (ROMP Ethics Study)
Bioethicists created videos and policy guidelines that aim to promote more ethical comparative-effectiveness research within medical practices.

REDESIGNING STROKE CARE (Stanford Clinical Excellence Research Center)
New stroke care strategies for prevention, acute treatment and post-stroke care could lower U.S. health-care costs by as much as $1.6 billion per year.

LOW-INCOME YOUTH YOGA PROGRAM (Office of Community Engagement)
Stanford researchers have brought yoga and mindfulness practices to students who experience post-traumatic stress disorder owing to difficult life circumstances.

HOME ASTHMA MONITOR (TueoHealth)
Spectrum-Biodesign pilot grant in 2016.
Accepted into StartX Accelerator.
$1.1M seed funding for company in 2017.
Now in clinical trials.

LAKOTA INDIAN BIO-REPOSITORY (Snyder Lab)
Aims to reduce health disparities by forming a Lakota community health advisory board, biobanking infrastructure, and education on health science and genetics.

AUTISM RESOURCE MAP (Wall Lab)
Many areas across the globe have few autism experts, leading to delayed care for kids who live there. Stanford scientists have launched a crowdsourcing project to pinpoint such geographic gaps, and find ways to fill them.

RECORD NUMBER TRAINED IN CLINICAL RESEARCH BOOTCAMP
Spectrum trained 87 residents, fellows and early-career faculty at its weeklong "Intensive Course in Clinical Research," deepening their understanding of study design, biostatistics, regulatory issues and bioethics.

LOW COST MICROSCOPE (Foldscope)
Spectrum-Biodesign pilot grant in 2013.
Company founded in 2016.
Goal: Ship 1M kits by end of 2017.

STATE-OF-THE-ART BIOBANK
A “lending library” of biological samples and genomic information could accelerate diagnostic and therapeutic research into rare diseases.

DRUG COMBO DEFEATS DENGUE VIRUS (Einav Lab)
A combination of two cancer drugs inhibited both dengue and Ebola viruses in mice in a study, funded by Spectrum, SPARK and the Stanford Child Health Research Institute.